Tresiba Market Report 2026

Tresiba Market Overview

• The Tresiba market growth in the historic period has been driven by rising prevalence of diabetes globally, increased diagnosis of type 2 diabetes • Market expansion is supported by increasing adoption of personalized diabetes treatment plans, rising use of digital diabetes management tools • Growth Driver: Rising Prevalence Of Diabetes Driving Demand For Advanced Insulin Therapies • Market Trend: Development Of Unbranded Biologics Enhances Affordability And Access To Insulin Therapy • North America was the largest region in 2025.

What Is Covered Under Tresiba Market?

Tresiba (insulin degludec) is a long-acting insulin used to manage diabetes mellitus in adults and children. It helps to control blood sugar levels in individuals with type 1 or type 2 diabetes by providing a steady release of insulin over a prolonged period. The main indication in the tresiba market are diabetes type 1 and diabetes type 2. Type 1 diabetes refers to a chronic autoimmune condition where the immune system mistakenly destroys insulin-producing beta cells in the pancreas, leading to insufficient insulin production and elevated blood sugar levels. The various distribution channels include hospital pharmacies, retail pharmacies, specialty pharmacies, and online pharmacies and, several end users encompass adults, geriatric patients, and pediatric patients.

What Is The Tresiba Market Growth Forecast?

The growth in the forecast period can be attributed to increasing adoption of personalized diabetes treatment plans, rising use of digital diabetes management tools, expansion of insulin access in emerging markets, growing focus on treatment adherence improvement, increasing investments in next-generation insulin products. Major trends in the forecast period include increasing adoption of ultra-long acting insulin therapies, rising preference for once-daily insulin regimens, growing focus on glycemic stability management, expansion of patient-centric diabetes care models, enhanced integration with digital glucose monitoring.

Global Tresiba Market Segmentation

1) By Indication: Diabetes Type 1, Diabetes Type 2 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Specialty Pharmacies, Online Pharmacies 3) By End User: Adults, Geriatric Patients, Pediatric Patients

What Are The Drivers Of The Tresiba Market?

The increase in the prevalence of diabetes is expected to propel the growth of the tresiba market going forward. Diabetes is a chronic medical condition when the body cannot properly regulate blood sugar (glucose) levels. The increasing prevalence of diabetes is attributed to factors such as sedentary lifestyles, unhealthy dietary habits, rising obesity rates, aging populations, and genetic predisposition. Tresiba is beneficial for addressing diabetes by providing patients with better glycemic control, reducing the risk of hypoglycemia, and offering flexible dosing options, which enhance treatment adherence and improve overall diabetes management outcomes. For instance, in June 2023, according to the Institute for Health Metrics and Evaluation, a US-based public health research institute, over half a billion people globally are living with diabetes in 2023. This number is expected to more than double, reaching 1.3 billion people by 2050. Therefore, the increase in the prevalence of diabetes is driving the growth of the tresiba industry. The rise in obesity is expected to propel the growth of the tresiba market going forward. Obesity is a medical condition characterized by excessive body fat that can negatively impact a person’s health. It is typically determined by measuring body mass index (BMI), a ratio of a person's weight to height. The rising prevalence of obesity is attributed to shifts in global food systems and eating habits, characterized by increased consumption of ultra-processed foods, sedentary lifestyles, and economic factors that make unhealthy food choices more readily available. Tresiba helps obese patients by providing long-acting insulin that aids in better glycemic control, reducing the risk of hypoglycemia, and supporting weight management through flexible dosing options. For instance, May 2024, Office for Health Improvement & Disparities, UK-based Government department, In 2022 to 2023, approximately 64.0% of adults aged 18 and over in England were classified as overweight or obesity. Therefore, the rise in obesity is driving the growth of the tresiba industry.

Key Players In The Global Tresiba Market

Major companies operating in the tresiba market are Novo Nordisk A/S

Global Tresiba Market Trends and Insights

The key trend in the tresiba market is the development of unbranded biologics to provide more affordable alternatives to branded medications by expanding access to insulin therapy while maintaining patient efficacy and safety, particularly in cost-sensitive markets. Unbranded biologics refer to biological medicines identical to their branded counterparts in molecular composition, quality, safety, and efficacy but are marketed without a specific brand name. For instance, in September 2022, Novo Nordisk A/S, a Denmark-based pharmaceutical company, announced the launch of its Food and Drug Administration (FDA)-approved unbranded biologic version of Tresiba (insulin degludec), a long-acting basal insulin designed to manage high blood sugar in patients aged one and older with diabetes. It is set to be available for prescription, the unbranded version aims to enhance affordability, particularly for uninsured and underinsured patients, as part of efforts to provide more accessible insulin options.

Regional Insights

North America was the largest region in the tresiba market in 2025. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Tresiba Market?

The tresiba market consists of sales of tresiba U-100, tresiba U-200, and pre-filled flextouch pen. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Tresiba Market Report 2026?

The tresiba market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the tresiba industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.